9/28/2018 Milatuzumab - DrugBank

Milatuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

IDENTIFICATION

Name Milatuzumab

Accession Number DB12943

Type Biotech

Groups

Investigational

Biologic Classification Protein Based Therapies (mAb)

Description

Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.

Protein chemical formula https://www.drugbank.ca/drugs/DB12943 1/8 9/28/2018 Milatuzumab - DrugBank

Not Available

Protein average weight

Not Available

Sequences

Not Available

Synonyms

Not Available

Categories

Amino Acids, Peptides, and Proteins

Antibodies

Antibodies, Monoclonal

Blood Proteins

Globulins

Immunoglobulins

Immunoproteins

Proteins

Serum Globulins

UNII 2OP4E0GC6V

CAS number

899796-83-9

PHARMACOLOGY

Indication

Not Available https://www.drugbank.ca/drugs/DB12943 2/8 9/28/2018 Milatuzumab - DrugBank

Pharmacodynamics Not Available

Mechanism of action Not Available

Absorption Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination Not Available

Half life Not Available

Clearance Not Available

Toxicity

Not Available

Affected organisms Not Available

Pathways Not Available https://www.drugbank.ca/drugs/DB12943 3/8 9/28/2018 Milatuzumab - DrugBank

Pharmacogenomic Effects/ADRs

Not Available

INTERACTIONS

Drug Interactions

ALL DRUGS APPROVED VET APPROVED NUTRACEUTICAL ILLICIT

WITHDRAWN INVESTIGATIONAL EXPERIMENTAL

Search

DRUG ↑↓ INTERACTION ↑↓ Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Milatuzumab.

Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Milatuzumab.

Alemtuzumab The risk or severity of adverse effects can be increased when is combined with Milatuzumab.

Anthrax immune globulin The therapeutic efficacy of Anthrax immune globulin human can be human decreased when used in combination with Milatuzumab.

Antithymocyte The risk or severity of adverse effects can be increased when immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) is combined with Milatuzumab.

Bacillus calmette-guerin The therapeutic efficacy of Bacillus calmette-guerin substrain substrain connaught live connaught live antigen can be decreased when used in combination antigen with Milatuzumab.

Bacillus calmette-guerin The therapeutic efficacy of Bacillus calmette-guerin substrain tice live substrain tice live antigen antigen can be decreased when used in combination with Milatuzumab.

Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Milatuzumab.

BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Milatuzumab.

Belimumab The risk or severity of adverse effects can be increased when Milatuzumab is combined with Belimumab. https://www.drugbank.ca/drugs/DB12943 4/8 9/28/2018 Milatuzumab - DrugBank

Showing 1 to 10 of 47 entries ‹ ›

Food Interactions

Not Available

REFERENCES

General References

Not Available

External Links PubChem Substance

347911409

Wikipedia

Milatuzumab

CLINICAL TRIALS

Clinical Trials

Search

PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓ 1 Active Not Treatment Acute Myeloid or Lymphoblastic Leukemia (AML or 1 Recruiting ALL) / Chronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL) / GVHD (Acute or Chronic) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)

1, 2 Completed Treatment Chronic Lymphocytic Lymphoma 1

1, 2 Completed Treatment Malignant Lymphomas 1

1, 2 Completed Treatment Multiple Myeloma (MM) / Myeloma, Plasma-Cell / 1 Plasmacytoma https://www.drugbank.ca/drugs/DB12943 5/8 9/28/2018 Milatuzumab - DrugBank

PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓

1, 2 Recruiting Treatment Lupus Erythematosus, Cutaneous / Lupus 1 Erythematosus, Discoid / Lupus Erythematosus, Systemic / Lupus Vasculitis, Central Nervous System / Nephritis, Lupus

1, 2 Unknown Treatment Chronic Lymphocytic Leukaemia (CLL) 1 Status

Showing 1 to 6 of 6 entries ‹ ›

PHARMACOECONOMICS

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices Not Available

Patents

Not Available

PROPERTIES

State

Not Available

Experimental Properties Not Available

https://www.drugbank.ca/drugs/DB12943 6/8 9/28/2018 Milatuzumab - DrugBank

TAXONOMY

Description Not Available

Kingdom

Organic Compounds

Super Class Organic Acids

Class Carboxylic Acids and Derivatives

Sub Class

Amino Acids, Peptides, and Analogues

Direct Parent Peptides

Alternative Parents

Not Available

Substituents Not Available

Molecular Framework Not Available

External Descriptors

Not Available

Drug created on October 20, 2016 19:30 / Updated on August 02, 2018 06:45

About https://www.drugbank.ca/drugs/DB12943 7/8 9/28/2018 Milatuzumab - DrugBank About DrugBank

DrugBank Blog Wishart Research Group Terms of Use

Privacy Policy

Support

FAQ Help Email Support

Commercial Products API Pricing

API Docs Data Licenses Support

This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc.

https://www.drugbank.ca/drugs/DB12943 8/8